Showing results (41-50 of 119) with videos related to

Sort By:
Pageof 12
Journal of Cancer Research and Therapeutics|December 1, 2021
Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinomaYusheng Wang, Jian Zhao, Hongmei Yu, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|May 11, 2019
Safety and Efficacy of Tianfoshen Oral Liquid in Non-Small Cell Lung Cancer Patients as an Adjuvant TherapyLei Zhao, Jing Wang, Huihui Li, et al.
World Journal of Surgical Oncology|July 27, 2022
Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysisYan Ma, Xiao Ma, Jingting Wang, et al.
Frontiers in Immunology|May 2, 2022
Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System CancersJingting Wang, Xiao Ma, Zhongjun Ma, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|February 28, 2018
Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cellsXiaojin Li, Anjian Xu, Huihui Li, et al.
Plos One|August 6, 2014
Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trialsQin Li, Han Yan, Wenting Liu, et al.
Immunogenetics|October 13, 2006
Association of interferon-gamma gene haplotype in the Chinese population with hepatitis B virus infectionMeiqiang Liu, Bangwei Cao, Hongkun Zhang, et al.
Asia-Pacific Journal of Clinical Oncology|May 12, 2023
Efficacy and adverse events of immune checkpoint inhibitors in esophageal cancer patients: Challenges and perspectives for immunotherapyYingjie Ma, Junxian Yu, Xiaoting Ma, et al.
Plos One|August 19, 2015
The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic AnalysisHan Yan, Huihui Li, Qin Li, et al.
Clinical Therapeutics|July 3, 2014
Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancerQin Li, Zhenyan Yuan, Han Yan, et al.
Pageof 12